. 2018 Mar 11;8(8):2278–2288. doi: 10.7150/thno.23544

Table 2.

Multivariate Cox proportional hazards regression model for the association of predicted responders with DFS and OS in the learning set (A) and the optimization set (B)

					PFS					OS
		n	n₁	n₂	coef	HR	95%-CI	p	p*	coef	HR	95%-CI	p	p*
(A) Learning set ^†
Predicted responders	R vs. NR	36	15	21	-1.755	0.17	0.06-0.51	0.001	0.002	-1.354	0.26	0.08-0.80	0.019	0.003
DFS	M1 vs. <24 mo	36	8	11	-1.000	0.37	0.09-1.43	0.150		-0.044	0.96	0.21-4.45	0.960
DFS	>24 mo vs. <24 mo	36	17	11	-0.107	0.90	0.35-2.32	0.830		0.560	1.75	0.63-4.87	0.280
Adjuvant chemotherapy	yes vs. no	36	18	18	-0.664	0.51	0.17-1.57	0.240		0.250	1.28	0.45-3.63	0.640
Histology	lobular+other vs. ductal	36	8	28	-0.559	0.57	0.14-2.28	0.430		-0.975	0.38	0.09-1.50	0.170
Tumor grade	3 vs. 1\|2\|unknown	36	16	20	-0.396	0.67	0.27-1.70	0.400		-0.282	0.75	0.32-1.77	0.520
Receptor status	HR+/HER2- vs. HR-/HER2-	36	26	10	0.030	1.03	0.33-3.26	0.960		-0.749	0.47	0.16-1.42	0.180
Type of metastases	visceral vs. non-visceral	36	25	11	1.039	2.83	0.88-9.11	0.082		1.393	4.03	1.11-14.63	0.034
Origin of specimen	metastasis vs. primary tumor	36	7	29	-0.810	0.45	0.13-1.58	0.210		-0.913	0.40	0.12-1.37	0.140

(B) Optimization set
Predicted responders	R vs. NR	48	34	14	-1.914	0.15	0.05-0.41	<0.001	0.006	-1.573	0.21	0.08-0.51	0.001	0.009
DFS	M1 vs. <24 mo	48	9	12	0.524	1.69	0.39-7.27	0.480		0.069	1.07	0.26-4.49	0.930
DFS	>24 mo vs. <24 mo	48	27	12	-0.056	0.95	0.33-2.73	0.920		-0.710	0.49	0.17-1.45	0.200
Adjuvant chemotherapy	yes vs. no	48	31	17	0.084	1.09	0.45-2.65	0.850		-0.304	0.74	0.30-1.83	0.510
ECOG PS	≥2 vs. 0\|1	48	4	44	1.026	2.79	0.75-10.42	0.130		1.761	5.82	1.50-22.56	0.011
Histology	lobular vs. ductal	48	6	37	1.196	3.31	1.05-10.41	0.041		1.236	3.44	1.07-11.11	0.039
Histology	other vs. ductal	48	5	37	1.669	5.31	1.73-16.30	0.004		1.160	3.19	1.05-9.70	0.041
Tumor grade	3 vs. 1\|2\|unknown	48	17	31	1.518	4.56	1.60-13.01	0.005		1.091	2.98	1.14-7.77	0.026
Receptor status	HR+/HER2- vs. HR-/HER2-	48	30	18	0.778	2.18	0.74-6.43	0.160		0.655	1.92	0.68-5.44	0.220
Type of metastases	visceral vs. non-visceral	48	31	17	0.741	2.10	0.86-5.10	0.100		0.508	1.66	0.67-4.11	0.270
Line of therapy	≥2^nd vs. 1^st	48	33	15	-0.356	0.70	0.31-1.57	0.390		0.135	1.14	0.53-2.47	0.730
Origin of specimen	metastasis vs. primary tumor	48	11	37	0.138	1.15	0.42-3.16	0.790		-0.150	0.86	0.36-2.08	0.740

* overall p-value using Wald test

† “ECOC PS” and “line of therapy” were not included in multivariate analysis in the learning set because all patients had ECOG PS 0 or 1 and all were treated 1^st-line.

DFS: disease-free survival; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ER: estrogen receptor; PR: progesterone receptor; CI: confidence interval; PFS: progression-free survival; OS: overall survival; coef is the coefficient in the Cox regression model for the respective variable; HR: hazard ratio (=exp(coef)); R: responder; NR: non-responder